1. COPD Population in US Primary Care: Data From the Optimum Patient Care DARTNet Research Database and the Advancing the Patient Experience in COPD Registry
- Author
-
Pace, Wilson D., Brandt, Elias, Carter, Victoria A., Chang, Ku-Lang, Edwards, Chelsea L., Evans, Alexander, Fox, Chester, Gaona, Gabriela, Han, MeiLan K., Kaplan, Alan G., Kent, Rachel, Kocks, Janwillem W.H., Kruszyk, Maja, Lievre, Chantal E. Le, Voti, Tessa Li, Mahle, Cathy, Make, Barry, Ratigan, Amanda R., Shaikh, Asif, Skolnik, Neil, Stanley, Brooklyn, Yawn, Barbara P., and Price, David B.
- Subjects
Drug therapy ,Risk factors ,Demographic aspects ,Chronic obstructive lung disease -- Demographic aspects -- Drug therapy -- Risk factors ,Lung diseases, Obstructive -- Demographic aspects -- Drug therapy -- Risk factors - Abstract
INTRODUCTION Chronic obstructive pulmonary disease (COPD) represents an important public health challenge that is preventable and treatable. (1) For the 16 million Americans who live with it, COPD carries a [...], PURPOSE To describe demographic and clinical characteristics of chronic obstructive pulmonary disease patients managed in US primary care. METHODS This was an observational registry study using data from the Chronic Obstructive Pulmonary Disease (COPD) Optimum Patient Care DARTNet Research Database from which the Advancing the Patient Experience COPD registry is derived. Registry patients were aged [greater than or equal to]35 years at diagnosis. Electronic health record data were collected from both registries, supplemented with patient-reported information/outcomes from the Advancing the Patient Experience registry from 5 primary care groups in Texas, Ohio, Colorado, New York, and North Carolina (June 2019 through November 2020). RESULTS: Of 17,192 patients included, 1,354 were also in the Advancing the Patient Experience registry. Patients were predominantly female (56%; 9,689/17,192), White (64%; 9,732/15,225), current/ex-smokers (80%; 13,784/17,192), and overweight/obese (69%; 11,628/16,849). The most commonly prescribed maintenance treatments were inhaled corticosteroid with a long-acting [[beta].sub.2]-agonist (30%) and inhaled corticosteroid with a long-acting muscarinic antagonist (27%). Although 3% (565/17,192) of patitents were untreated, 9% (1,587/17,192) were on short-acting bronchodilator monotherapy, and 4% (756/17,192) were on inhaled corticosteroid monotherapy. Despite treatment, 38% (6,579/17,192) of patients experienced 1 or more exacerbations in the last 12 months. These findings were mirrored in the Advancing Patient Experience registry with many patients reporting high or very high impact of disease on their health (43%; 580/1,322), a breathlessness score 2 or more (45%; 588/1,315), and 1 or more exacerbation in the last 12 months (50%; 646/1,294). CONCLUSIONS Our findings highlight the high exacerbation, symptom, and treatment burdens experienced by COPD patients managed in US primary care, and the need for more real-life effectiveness trials to support decision making at the primary care level. Key words: APEX; characterization; electronic medical records; patient reported outcomes; primary care
- Published
- 2022
- Full Text
- View/download PDF